13G Filing: Empery Asset Management, LP and Eyegate Pharmaceuticals Inc (EYEG)

Page 9 of 9

Page 9 of 9 – SEC Filing

EXHIBIT 1

JOINT ACQUISITION STATEMENT
PURSUANT TO RULE 13d-1(k)

The undersigned
acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent
amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing
additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such
amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible
for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason
to believe that such information is inaccurate.

DATED: June 14, 2017

EMPERY ASSET MANAGEMENT, LP
By: EMPERY AM GP, LLC, its General Partner
By: /s/ Ryan M. Lane                                      
Name:  Ryan M. Lane
Title:  Managing Member
/s/ Ryan M. Lane                                            
Ryan M. Lane
/s/ Martin D. Hoe                                            
Martin D. Hoe

Follow Kiora Pharmaceuticals Inc (NASDAQ:KPRX)

Page 9 of 9